CTOR
Citius Oncology, Inc.
CTOR
Citius Oncology, Inc.
$7.1 Million in revenue for the first nine months of fiscal 2026 from commercial sales of LYMPHIR ® $17 million in cash and cash equivalents as of June 30, 2026 Expanded LYMPHIR commercial and medical
$7.1 million in revenue for the first nine months of fiscal 2026 as the LYMPHIR ® launch progresses Strong institutional demand drives growth in total vials ordered and number of institutions ordering
Expanded commercial and medical affairs teams expected to be fully operational throughout the U.S. by August CRANFORD, N.J., July 21, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Na